ALNY Q4 2017 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$38M+117.3% YoY

Gross Profit

$38M100.0% margin

Operating Income

-$147M-388.4% margin

Net Income

-$142M-375.0% margin

EPS (Diluted)

$-1.48

QoQ Revenue Growth

+121.8%

Cash Flow

Operating Cash Flow

-$103M

Free Cash Flow

-$124M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$2.0B

Total Liabilities

$228M

Stockholders' Equity

$1.8B

Cash & Equivalents

$645M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38M	$17M	+117.3%
Gross Profit	$38M	$17M	+117.3%
Operating Income	-$147M	-$115M	-27.6%
Net Income	-$142M	-$113M	-25.9%